13.7% Average Loss With Semaglutide in Knee Osteoarthritis
STEP 9 evaluated weekly semaglutide 2.4 mg in people who had obesity, moderate knee osteoarthritis, and at least moderate knee pain. It reported weight and pain-score improvements under a 68-week protocol. The findings are not an osteoarthritis treatment recommendation or evidence that semaglutide changes joint structure or disease progression.
At week 68, mean body-weight change was −13.7% with semaglutide and −3.2% with placebo; WOMAC knee-pain score change was −41.7 and −27.5 points, respectively.
The between-group difference was −10.5 percentage points for weight and −14.2 points for knee pain on the 0-to-100 WOMAC scale. SF-36 physical-function score improved by 12.0 points with semaglutide and 6.5 with placebo. Adverse events causing permanent discontinuation occurred in 6.7% and 3.0%, respectively, most commonly gastrointestinal disorders.
Turn the study result into a better program comparison
If this result leads you to explore GLP-1 care, compare the program details the trial did not test: clinician access, medication status, lifestyle support, public price terms, follow-up, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 407 adults with obesity, moderate clinical and radiographic knee osteoarthritis, and at least moderate knee pain
- Follow-up
- 68 weeks
- Treatment comparison
- Once-weekly subcutaneous semaglutide 2.4 mg or placebo, with reduced-calorie-diet and physical-activity counseling in both groups
- Study design
- Phase 3, multicenter, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
This study did not replace knee evaluation, physical therapy, pain care, or orthopedic care. It does not determine whether semaglutide is appropriate for an individual, what a provider can prescribe, or what insurance covers. Those decisions require a licensed clinician and current plan terms.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The trial compared semaglutide with placebo rather than an intervention producing matched weight loss, so it cannot isolate whether pain differences were mediated by weight loss or another drug effect.
- It enrolled adults with obesity, moderate radiographic knee osteoarthritis, and at least moderate pain, so results do not directly apply outside those characteristics.
- The 68-week results do not establish longer-term durability of weight or pain changes, and the primary outcomes did not establish changes in knee-joint structure or osteoarthritis progression.
- The study does not compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual treatment outcomes.
- The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine